Targeting Tumor Metabolism in Lymphoma
This research project in the University of Iowa/Mayo Clinic Lymphoma SPORE is focused on developing new treatments for lymphoma that aim to interfere with signal pathways that drive the use of glucose.
Some lymphomas lose a regulator of growth called TNFR-associated factor 3 (TRAF3) and activate a regulator of many pathways (including glucose) called glycogen synthase kinase 3 (GSK3). The SPORE project team is testing a new GSK3 inhibitor to learn whether it can inhibit lymphoma tumor growth and improve survival in patients.
The project co-leaders are:
The co-investigators are: